Niklason Laura E

HUMA CEO Niklason sells entire 2.24M-share stake (2,241,045 shares) for $3.7M across 3 days; stock now -76.9% from 52-week high.

Laura E Niklason, HUMA's President, CEO and Director, executed 3 separate sales totaling 2,241,045 shares for $3,733,191.10 at prices ranging from $1.83 to $1.58 on August 18–20, 2025, reducing her holdings from 2.24M shares to 0 shares (a 100.0% reduction). The company faces material headwinds: latest quarterly revenue was only $301,000.00, net income was negative $37,658,000.00, and the full-year result was unprofitable. At the transaction's blended average price of $1.67, the stock is currently -76.9% from its 52-week high of $7.05 and down -29.1% over 30 days. Niklason's cross-ticker sell track record shows a 93.75% well-timed rate over 90 days, and her prior 5 trades at HUMA included 4 well-timed sales at the 90-day mark, suggesting a pattern of selling ahead of declines. The complete liquidation of the CEO's personal stake—coupled with severe revenue contraction, substantial ongoing losses, and sharp recent price deterioration—warrants investor scrutiny.

HUMA CEO Laura E Niklason bought 1,797 shares at $4.44 on 2024-11-19; stock down -20.1% in 30 days, -37.7% in 90 days.

Laura E Niklason, CEO and President, purchased 1,797 shares for $7,978.68 at $4.44, adding 0.7% to her post-transaction holdings of 243.9K shares on 2024-11-19. However, the stock has declined sharply since the purchase: -20.1% over 30 days and -37.7% over 90 days, trading 53.7% below its 52-week high of $9.46. Critically, this buy occurred amid a pattern of recent insider activity at HUMA: the CEO sold shares on 2024-11-20, 2024-11-19, and 2024-11-18—immediately before and after this purchase. The company is unprofitable (net income of $-39.2M on revenue of $241.0K in the latest quarter) and trades at a $551.3M market cap, raising questions about the substance of a buy signal when senior management is simultaneously executing multiple sales at this juncture.

HUMA CEO Laura Niklason sells 1,500,000 shares ($6.6M) over 3 days; stock down 53.4% from 52-week high, company unprofitable with -$39.2M net income.

Niklason, the President, CEO and Director, executed 3 separate sales totaling 1,500,000 shares (1.50M shares) for $6,606,799.34 ($6.6M) between November 18–20, 2024, reducing her holdings by 46.4% from 3,230,884 shares (3.23M shares) to 1,730,884 shares (1.73M shares). The timing is significant given the stock's deteriorating performance: HUMA is down 53.4% from its 52-week high of $9.46, down 17.4% over the past 30 days, and down 31.1% over the past 90 days. The company's financial position adds context—it reported revenue of only $241,000.00 ($241.0K) in its latest quarter and a net loss of $-39,202,000.00 ($-39.2M) over the most recent full fiscal year, making the CEO's significant exit from a material position worthy of investor attention. Across her prior 16 open-market sells at all tickers, the insider has demonstrated a 90.91% well-timed rate, suggesting a pattern of selling before declines, though her same-ticker history at HUMA does not yet provide measurable longer-term outcomes on which to assess her timing acuity at this company specifically.

CEO Laura Niklason sold 446,378 shares at blended average $5.30 for $2.4M on 2024-09-09/10

Laura Niklason, President, CEO and Director, executed 2 separate sales totaling 446,378 shares for $2,364,520.70 at an average price of $5.30 per share. The sale reduced her holdings by -12.1% versus pre-transaction levels. The company is deeply unprofitable with quarterly revenue of $241,000.00 against a net income of $-56,663,000.00, creating structural fundamental concerns. Notably, her cross-ticker track record shows a 71.43% well-timed sell rate historically (prior sales were followed by declines), and her single prior measurable sale at this ticker on 2024-06-12 occurred before a -28.1% 90-day decline, suggesting a pattern of selling ahead of weakness. Current price at $5.69 is -39.8% from the 52-week high, and the stock has declined -14.0% over 30 days and -21.0% over 90 days, placing the transaction in the context of deteriorating momentum.

CEO Laura E Niklason bought 1,222 shares of HUMA at $6.54; stock down 41.4% from 52-week high, trading below transaction price.

Laura E Niklason, President, CEO and Director, purchased 1,222 shares at $6.54 on 2024-08-29, adding 0.5% to her 240.8K share position. The current price of $5.54 is 41.4% below the 52-week high and 15.3% below her transaction price, indicating deterioration since the purchase. Her cross-ticker track record shows 2 prior buys with an average 90-day return of -11.3% and a 0% win rate, suggesting a pattern of poorly-timed open-market acquisitions. At HUMA specifically, she has executed 5 prior trades dominated by sales—most recent sales on 2024-08-27, 28, and 29 (same dates as this buy or adjacent)—which creates a puzzling mix of simultaneous buying and selling activity. The company reported revenue of $241.0K in the latest quarter against net income of $-56.7M, reflecting persistent unprofitability and minimal revenue relative to the $661.2M market cap.

CEO Laura E Niklason sells 881,878 shares ($5.7M) over 3 days; stock down 25% in 30 days, 35% from 52-week high.

Laura E Niklason, President, CEO and Director, executed 3 separate sales totaling 881,878 shares for $5,724,139.46 (blended average $6.49 per share) on August 27–29, reducing her holdings by 19.3% from 4,559,140 to 3,677,262 shares. The selling occurred as the stock was already under pressure: the current price is $6.15, down 35.0% from the 52-week high of $9.46 and off 25.0% in the past 30 days. Against this backdrop, Humacyte reports severe financial distress: latest quarterly revenue of $241,000.00 and net income of $-56,663,000.00, with the company unprofitable over its most recent full fiscal year. Her prior trades at HUMA show a pattern of selling into weakness (5 trades in recent months, 4 of which were sales); her cross-ticker track record shows 14 prior sells with a 55.56% well-timed rate at the 90-day mark and an average 30-day return of -11.8%, indicating prior sells have generally preceded further declines. The near-simultaneous three-day sale of a substantial equity block amid deteriorating fundamentals and downward price momentum warrants attention.